Table 2. Associations between plasma and CSF Aβ biomarkers.
| All cases | Control | SCD | MCI | AD | |
|---|---|---|---|---|---|
| Aβ42 | r = 0.274,p < 0.00139 (35, 43) | r = 0.188,p = 0.00239 (34, 44) | r = 0.182,p = 0.01647 (40, 54) | r = 0.270,p < 0.00148 (29, 46) | r = 0.288,p = 0.03013 (10, 16) |
| Aβ40 | r = 0.136,p = 0.00124 (21, 26) | r = 0.114,p = 0.059 | r = 0.120,p = 0.114 | r = 0.083,p = 0.225 | r = 0.349,p = 0.00815 (11, 18) |
| Aβ42/Aβ40 | r = 0.215,p < 0.0011.9 (1.4, 2.4) | r = 0.166,p = 0.0061.5 (0.6, 2.5) | r = 0.160,p = 0.0351.8 (0.8, 2.7) | r = 0.202,p = 0.0032.8 (2.4, 3.2) | r = −0.003,p = 0.981 |
AD, Alzheimer’s disease; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; SCD, subjective cognitive decline.
Plasma and CSF Aβ were measured using Simoa and Euroimmun immunoassays, respectively. Associations between plasma and CSF Aβ were first evaluated with Pearson’s correlation analysis and if significant correlations were found further investigated using RMA adjusting for age and gender. Data are presented as r, p from Pearson’s correlation analysis and slope estimates (95% CI) from RMA; significant results are shown in bold.